Geropharm: Petr Rodionov. Developing and producing Russian innovative drugs for treatment of socially significant diseases




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Geropharm: Petr Rodionov. Developing and producing Russian innovative drugs for treatment of socially significant diseases
Released on: June 06, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelevision News Review, filmed at Bio Conference 2013, in Chicago, USA, Fintan Walton talks to Petr Rodionov of Geropharm
Product pipeline
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at the BIO Convention, in Chicago, in 2013. On this show I have Petr Rodionov, who is CEO of a company called Geropharm, which is based in Russia, welcome.
Petr Rodionov:
Yes, thank you.
Fintan Walton:
Petr, it's great to hear about a biotech company in Russia one which you're the founding CEO of, could you tell us about the origins of Geropharm, and it's history as of up to now?
Petr Rodionov:
Yes, the Geropharm company was founded in 2001 originally to promote Russian original drug which was developed in Russian Military Academy and we were total manufacturing until 2008 when we brought our biotech division together and now in 2009 we started the investment and putting facilities in the Moscow region which is South of Moscow and now late this year, September this year, we are opening a facility which is brand new facility modern according to cGMP standards in Moscow, in the Moscow region here.
Fintan Walton:
Okay. So the original product that you've taken to market and you've got a product that went to the market?
Petr Rodionov:
Yes, we went with this original product in Russia.
Fintan Walton:
Could you tell us a bit about the product?
Petr Rodionov:
Yes this product is to in CNS area, it's a stroke and head trauma product, which we commercialized very successfully in Russia and CIS countries, so we kept subsidiaries in all CIS countries at the moment, and the turn over around 80 million US dollars on the sales on that on the product in those countries.
Fintan Walton:
So now when you take a company like Geropharm you try and develop it within Russia, you've got your own market for this first product you've launched, you've got backers coming in and backing the company itself, putting the finance into the company, so what is your, what's your focus now? What's your pipeline, your product pipeline like?
Petr Rodionov:
So we now focused like a niche company in two major therapeutic areas, one is the CNS very wide understanding on CNS it's a all kind of drugs which can influence CNS area, and then diabetes these are two major therapeutic areas and in both we develop a very wide portfolio at the moment, we have established our own R&D centre in a special economy zone in Saint Petersburg in late 2011, so it's around 60 people are now involved and scientists which are working on developing of drugs in these two major areas.
Fintan Walton:
So they are in preclinical stage?
Petr Rodionov:
This is mainly a preclinical stage , it's a pharma development so drug development itself and some preclinical studies and some of them, most of them we outsource around the world, so some of them may be in Japan, in Europe, in Russia, so we want to provide very proof data so validate the data.
Program in diabetes space
Fintan Walton:
Okay, and then you've also got to, you've got interest in diabetes as well, would you tell us about that program?
Petr Rodionov:
We this, there was a company founded in 1998 which was supposed to bring to the market recombinant insulins, but it was doing not so successfully and then in 2008 we decided to bring that company in our group of companies and to invest some money to bring to the market state of the art this technology and the recombinant insulins and we already have registered it in Russia and we will start to commercialize in September, and very similar to what we started in 2001 is in 2013 that nobody believed that we can be successful in this area, because it's very difficult and we'll see you know because this year we started to have the results, it's a not too long time to wait, then we have in portfolio now in two more insulins which were under development, it's lispro and glargine which are the top insulins at the moment worldwide and we are to present them to the market in a few years time.
Partnership strategy
Fintan Walton:
So you are in the area of biosimilars isn't it?
Petr Rodionov:
Yes we are in the area of biosimilars as well.
Fintan Walton:
Okay, so you are looking to take more similar type of products which are now off patent and going into compete in that particular space?
Petr Rodionov:
No, we just totally want to focus because we are rather a small company, so still focusing on CNS and diabetes, so in diabetes, in biosimilars there are insulins and there is a wide portfolio of some other drugs which we will bring to Russian market and we are negotiating with some companies just to widen the portfolio.
Fintan Walton:
Okay. So as part of your strategy you are looking for partnerships as well to partner with other companies outside Russia?
Petr Rodionov:
Yes, we do, outside of Russia we do look for partnerships, so both ways one way is to bring something to Russian market and the opposite way we are eager to export insulins, but everyone waits for to see how it will work in Russia, because insulins is a very sensitive area and everybody wants to see how successful can we be in our own market with our recombinant insulins.
Petr Rodionov's views: Biotech environment in Russia and initiatives by Russian government
Fintan Walton:
Right, and for a company like yours, developing a company like yours in Russia, what is the environment like, I mean obviously we come to California there is a lot of biotech companies, so do you have many similar companies, do you have to feel isolated or you may be?
Petr Rodionov:
No, we don't feel isolated, until 2008 there was no Russian local pharmaceutical industry or biotech industry recognized by anyone. In 2008 it happened where the world crisis and the Russian crisis as well so the economy collapsed and then everything went down and the only industry which didn't go down in Russia was the pharmaceutical, one among the few, and then the government looked at that like carefully and said okay there is actually there is an industry they are like producers which are doing something and they decided to, then that pharma 20-20 program started to be discussed with all the players with the industry, there were many people who were very skeptical about that, mainly international companies, but we believed and now the attitude to that has changed dramatically, so nobody now doubts that it will happen and everybody believes that the changes will come or they are already taking place and there is not only our company there is a lot more who invests in putting R&D centers, in innovation, in putting new facilities, so there is then.
Fintan Walton:
So there is an initiative to?
Petr Rodionov:
Yes, it was initiative which some people responded like some investors and we are among the first ones to, has believed that it will happen, so it cannot be no longer on the market which is growing very, very fast and it's supposed to be ranked at number 11 in 2011 and it will be like number 8 in 2016 among all pharmaceutical markets around the world, so we cannot be the model of just selling the drugs.
Fintan Walton:
Right.
Petr Rodionov:
You have to do something in return, so and I believe that.
Fintan Walton:
So what is the initiative that the Russian government has taken, what are they doing to create this?
Petr Rodionov:
What they are doing they are trying to put the clear vision to everyone how the industry will develop. So that is the first point before that there was no focus, you know everybody, there was no discussion even which can brought all the industry together to discuss how we should develop, so first point is clear vision how it will change. Second is they are putting some effort and some funds, state funds to help to develop some drugs in bio, in bio - industry, in chemicals, in small molecules so investing some funds to help Russian companies, local companies boost.
Fintan Walton:
Okay.
Petr Rodionov:
Yes so they are putting all those funds.
Fintan Walton:
So that's in the form of grants?
Petr Rodionov:
And more over there is a legislation to change to give a understanding what is a local product and to fulfill it with some privileges, because there is obviously there is a aim to make improved substitution.
Fintan Walton:
Sure.
Petr Rodionov:
Yes.
Fintan Walton:
Right, so it's helping to build an industry basically in Russia?
Petr Rodionov:
There is a statement that if you want to create an industry you need to give the market and the market, there is a market and it's growing at least 10% per year or even more.
Future plans
Fintan Walton:
So for you now, you are taking your business forward, what's your vision now for the next few years, where would you like to take Geropharm into the future?
Petr Rodionov:
For that we have a strategy for five-years, so we want to develop very strong portfolio and very strong pipeline in those two major areas, then we are working on, very hard on bringing those two new insulins to the market and also outside Russia, so we want to export it, we believe that if we do it very well and according to international standards and do a very strong clinical data it should be not only for Russia, or of CIS, it should be competitive in other countries, so we want to push it outside Russia as well.
Fintan Walton:
You are looking for partners to do that?
Petr Rodionov:
Yes and we have already participated in a number of events showing that we have already the technology and we see the interest to that actually.
Fintan Walton:
Petr Rodionov, thank you very much indeed for coming on the show.
Petr Rodionov:
Yes, thank you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
Petr Rodionov
Chief Executive Officer
At the time of recording this PTV interview Petr Rodionov serves as Chief Executive Officer of Geropharm. Petr Rodionov was born in 1978 in Leningrad (Saint - Petersburg). He graduated from St. Petrsburg State University, Economics Department, then underwent a study course in Yale School (1995 " 1996). Since 2001 Mr. Rodionov has been lead-managing a pharmaceutical company named GEROPHARM. Under his leadership GEROPHARM has developed from a small company to the effective business structure. Now the company is one of the prominent players and experts on the pharmaceutical market. Now GEROPHARM is among the top 20 leading Russian pharmaceutical producers. According to the rating "TehUspeh" (2012) the company entered the Top-30 of Russian high-growth companies GEROPHARM is a resident of St. Petersburg pharmaceutical cluster and of "Northern" Biopharmaceutical cluster Development Center in Moscow District.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Geropharm
Geropharm is among TOP 20 leading Russian pharmaceutical producers. Its dynamic growth since its foundation in 2001 allowed it to become one of the prominent player in pharmaceutical market and expert in pharmaceutical community. According to TekhUspekh rating made in 2012, Geropharm is among TOP 30 fastest growing innovative Russian companies. Today Geropharm is a group of companies that develop and produce Russian innovative drugs for treatment of socially significant diseases and generics which have priority in terms of import substitution. Strategic objectives of the company are similar to the current goals of the industry. These goals were determined within the state federal programs PHARMA-2020, BIO-2020.